Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gynaecological cancers

1807 - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group


20 Oct 2018


Poster Discussion session - Gynaecological cancers


Rare Cancers

Tumour Site

Ovarian Cancer


Thibault de La Motte Rouge


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


T. de La Motte Rouge1, F. Derquin1, A. Floquet2, J. Edeline1, J. Lotz3, J. Alexandre4, P. Pautier5, G. Ferron6, E. Boissier7, C. Lefeuvre-Plesse1, H. Vegas8, A. Patsouris9, E. Kalbacher10, D. Berton-Rigaud11, A. Hardy Bessard12, V. Lavoué13, I.L. Ray-Coquard14

Author affiliations

  • 1 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2 Oncologie Médicale, Institute Bergonié, 33076 - Bordeaux/FR
  • 3 Medical Oncology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 4 Medical Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 5 Medecine, Gustave Roussy, 94805 - Villejuif/FR
  • 6 Surgical Department, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 7 Medical Oncology, European George Pompidou Hospital, 75015 - Paris/FR
  • 8 Medical Oncology, CHRU Bretonneau, 37044 - Tours/FR
  • 9 Medical Oncology, Centre Paul Papin, 49100 - Angers/FR
  • 10 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 11 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 12 Medical Oncology, Hôpital Privé des Côtes d'Armor, 22190 - Plérin/FR
  • 13 Gynaecology Department, CHU Anne-de-Bretagne, 35203 - Rennes/FR
  • 14 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR

Abstract 1807


In France, a national network (TMRO) has been set up since 2010 to prospectively monitor the management of rare ovarian tumors. In FIGO stage I MOGCT patients (pts), the role of adjuvant chemotherapy (adj CT) remains debated. Here, we aimed to define the impact of adj CT in stage I pts.


All MOCGT prospectively recorded in 13 of the most important centers of the TMRO network were analysed.


Overall, 147 pts were registered and most of the pts (n = 101, 69%) were stage I at diagnosis. Median follow-up period was 51 months. Complete peritoneal staging (peritoneal washings, biopsies or omentectomy) was performed in 77/101 pts and surgery with fertility preservation in 94/101 pts. Thirty nine (39%) pts had immature teratoma, 26 (26%) had yolk sac tumors (YST), either pure (n = 16) or mixed (n = 10), 24 (24%) had pure dysgerminoma and 3 had others mixed tumors. Fifty-nine pts had stage IA while 34 presented with stage IB-C. Adj CT was administered to 28/60 and 31/33 stage IA-B and IC pts. In the 34 pts treated with surgery only, 12 (35.3%) relapsed: 6/16 (37.5%) pts with pure dysgerminoma, 3/15 (20%) with immature teratoma, and 3/3 with YST. All relapsed pts were initially staged IA. No relapse was observed following salvage chemotherapy. The 5-year-event free survival (EFS) rates were respectively 94.4% in pts treated with adjuvant chemotherapy and 54.6% in pts who underwent surgery followed by surveillance only (p < 0,00001). All but 1 relapsed pts underwent chemotherapy. The 5-year overall survival rates were similar with respectively 96.3% versus 97.8% (NS). Twenty-two stage FIGO I pts could be spared from any chemotherapy.


Most MOGCT stage I pts will be cured. Active surveillance is associated with an excellent survival outcome in MOGCT. This should be the preferred option for immature teratoma. In pure dysgerminoma, relapse rate was higher than previous reports, emphasizing the need to discuss with the patient the benefit of not having adj CT (i.e. the avoided risk weighed against the risk of relapse and delayed treatment). Adj CT remains recommended for all pts with YST.

Clinical trial identification

Legal entity responsible for the study

T. de La Motte Rouge.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.